Replies to post #170295 on Biotech Values

[ciotera]

Re: HCV throughput

I disagree. Time spent per HCV patient is going to go down appreciably (both for physicians and their support staff) because of the simpler, shorter and safer IFN-free treatments. And 90% cure rates mean few people stick around needing follow-up/monitoring post-treatment.

That the all-oral regimens will allow the same number of per-patient visits to be compressed into a shorter period does not increase the number of HCV patients a given physician can treat during a given period of time

I don't understand your logic. Even if I grant you that physicians will not appreciably increase the number of patients they have on therapy simultaneously (although I think they will), won't reducing the length of treatment to 12 weeks (compressing visits to a shorter period) mean that they can have more treatment cohorts during a given 12 month window?